Arbutus Biopharma (ABUS)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	31.85 mm	31.85 mm	31.85 mm	31.85 mm	31.85 mm	31.85 mm
Cash burn (monthly)	10.31 mm	(no burn)	7.15 mm	6.93 mm	6.91 mm	5.99 mm
Cash used (since last report)	52.41 mm	n/a	36.32 mm	35.21 mm	35.13 mm	30.42 mm
Cash remaining	-20.57 mm	n/a	-4.47 mm	-3.36 mm	-3.28 mm	1.43 mm
Runway (months of cash)	-2.0	n/a	-0.6	-0.5	-0.5	0.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

ABUS institutional ownership history Ownership history

75.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	152	143	+6.3%
Opened positions	22	29	-24.1%
Closed positions	13	15	-13.3%
Increased positions	53	44	+20.5%
Reduced positions	41	32	+28.1%

13F shares	Current	Prev Q	Change
Total value	338.52 bn	386.13 bn	-12.3%
Total shares	142.59 mm	139.61 mm	+2.1%
Total puts	666.10 k	525.00 k	+26.9%
Total calls	649.10 k	2.31 mm	-71.9%
Total put/call ratio	1.0	0.2	+352.1%

Largest owners	Shares	Value	Change
ROIV Roivant Sciences	38.85 mm	$160.83 mm	0.0%
MS Morgan Stanley	22.59 mm	$73.86 bn	+4.0%
Whitefort Capital Management	13.24 mm	$43.30 bn	+2.9%
BlackRock	12.94 mm	$42.31 bn	+5.9%
Vanguard	8.98 mm	$29.37 bn	+0.7%
Kairos Capital Management	8.74 mm	$28.58 bn	+4.2%
STT State Street	5.03 mm	$16.44 bn	+14.1%
Geode Capital Management	3.48 mm	$11.39 bn	+1.0%
BlackBarn Capital Partners	2.34 mm	$7.66 bn	+13.1%
Rubric Capital Management	1.68 mm	$5.50 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
FourWorld Capital Management	1.23 mm	-1.75 mm	-58.7%
Rangeley Capital	1.46 mm	+1.46 mm	NEW
Adage Capital Partners GP, L.L.C.	1.65 mm	-1.25 mm	-43.1%
MS Morgan Stanley	22.59 mm	+878.47 k	+4.0%
JPM JPMorgan Chase & Co.	896.26 k	+806.67 k	+900.4%
BlackRock	12.94 mm	+718.70 k	+5.9%
STT State Street	5.03 mm	+619.50 k	+14.1%
ADAR1 Capital Management	1.55 mm	-534.52 k	-25.6%
Boothbay Fund Management	162.28 k	-450.00 k	-73.5%
Whitefort Capital Management	13.24 mm	+373.95 k	+2.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ABUS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Feb 25	Karen Sims	Common Shares	Grant	Acquire A	No	No	0	49,300	0.00	155,494
14 Feb 25	Karen Sims	Stock Option Common Shares	Grant	Acquire A	No	No	3.29	200,300	658.99 k	200,300
14 Feb 25	McElhaugh Michael J.	Common Shares	Grant	Acquire A	No	No	0	177,000	0.00	1,658,003
14 Feb 25	McElhaugh Michael J.	Stock Option Common Shares	Grant	Acquire A	No	No	3.29	718,800	2.36 mm	718,800
14 Feb 25	J. Christopher Naftzger	Common Shares	Grant	Acquire A	No	No	0	54,300	0.00	140,544
14 Feb 25	J. Christopher Naftzger	Stock Option Common Shares	Grant	Acquire A	No	No	3.29	220,300	724.79 k	220,300
14 Feb 25	Hastings David C	Common Shares	Grant	Acquire A	No	No	0	90,100	0.00	249,824
14 Feb 25	Hastings David C	Stock Option Common Shares	Grant	Acquire A	No	No	3.29	365,800	1.20 mm	365,800
4 Feb 25	McElhaugh Michael J.	Common Shares	Sell	Dispose S	No	Yes	3.283	23,790	78.10 k	1,481,003

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Arbutus Biopharma Appoints Lindsay Androski As CEO Amid Major Board Reshuffle

25 Feb 25

In addition to Ms. Androski, four new directors have joined the board: Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija. In connection with the appointment of these new directors, all members of the

HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

21 Jan 25

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

Arbutus Biopharma Held $123M In Cash Balance, Eying Placebo-Controlled Phase 2b Clinical Trial

13 Jan 25

Imdusiran (RNAi therapeutic)At the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® in November 2024, the Company presented new data from its IM-PROVE I Phase 2a clinical trial

Whitefort Capital Sends Letter To Arbutus Biopharma Board Of Directors; Believes Now Is The Time For Arbutus To Pursue A License And Collaboration Agreement With A Strategic Partner And Explore All Options For HBV Portfolio

3 Dec 24

Press releases

From Benzinga Pro

Arbutus Provides 2025 Corporate and Financial Update

13 Jan 25

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) --